The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Exelixis; Genentech
Stock and Other Ownership Interests - Exelixis; Roche
Patents, Royalties, Other Intellectual Property - Exelixis
SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA mutant tumors.
 
Jose Baselga
No Relationships to Disclose
 
Javier Cortes
Honoraria - Celgene; Eisai; Novartis; Roche Pharma AG
Consulting or Advisory Role - Celgene; Roche Pharma AG
 
Michelino De Laurentiis
Honoraria - AstraZeneca; Novartis; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Celgene; Genomic Health; Novartis; Roche Pharma AG
 
Véronique Diéras
Honoraria - Roche/Genentech
Consulting or Advisory Role - Roche/Genentech
Speakers' Bureau - Roche/Genentech
 
Nadia Harbeck
Honoraria - Amgen; Celgene; NanoString Technologies; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Celgene; Genomic Health; Novartis; Roche/Genentech; Sandoz; Wilex
Research Funding - Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Young-Hyuck Im
No Relationships to Disclose
 
William Jacot
Consulting or Advisory Role - Eisai
 
Ian E. Krop
Research Funding - Genentech/Roche
 
Sunil Verma
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Amgen; AstraZeneca; Eisai; Lilly; Novartis; Roche/Genentech
Speakers' Bureau - Novartis
Research Funding - Sanofi
 
Timothy R. Wilson
Employment - Genentech
Stock and Other Ownership Interests - Roche Pharma AG
 
Ray Lin
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche/Genentech
Travel, Accommodations, Expenses - Roche/Genentech
 
Frauke Schimmoller
No Relationships to Disclose
 
Jerry Y. Hsu
Employment - Genentech
Stock and Other Ownership Interests - Roche Pharma AG